Wednesday, July 8, 2026

Drug profile · INN

teniposide

teniposide (VUMON) is a dna topoisomerase ii inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved NMPA: clinical trials
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — teniposide
US status
approved
Class
Route
INJECTION
Patents
0
Programs
2
Data quality
0.84

Quick answer

teniposide (VUMON) is a dna topoisomerase ii inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN teniposide
Brand VUMON
Mechanism DNA topoisomerase II inhibitor
Target DNA topoisomerase II
Route INJECTION
Formulation INJECTABLE

Mechanism of action

DNA topoisomerase II inhibitor

Primary target: DNA topoisomerase II

Approval history

Authority Status Date
FDA approved
NMPA clinical trials

Pipeline programs

  1. Teniposide administration Phase 2 · Chinese Academy of · Extensive-stage Small Cell Lung Cancer (ES-SCLC)
  2. 2024474 Unknown · First People's Hospital · Primary Central Nervous System Lymphoma (PCNSL)

Related & competitor drugs

  1. etoposide DNA topoisomerase II inhibitor
  2. dexrazoxane hydrochloride DNA topoisomerase II inhibitor
  3. dexrazoxane Various (V03)

Frequently asked questions

What is teniposide?

teniposide (VUMON) is a dna topoisomerase ii inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for teniposide?

VUMON is a marketed brand name for teniposide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of teniposide?

teniposide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.